Lassa fever vaccine.
Lassa fever remains a serious challenge to public health in West Africa threatening both local residents in rural areas and those who serve them, particularly medical care providers. Given the ecology of the rodent host and conditions in the endemic area, a vaccine is mandatory for control. The challenge is to overcome the scientific, political and economic obstacles to producing a human use vaccine candidate. There are some scientific issues to resolve. It is known that the G-protein confers protection but we do not know its duration. If the N-protein is also included there may be a better duration of protection but it is unclear whether the N-protein as a vaccine may possibly enhance the infection. The original vaccinia vector must be replaced by new vectors, chimeras or by delivering DNA in some format. A live vaccine is attractive because it can confer protection in a single shot. A killed vaccine is more stable, particularly for distribution in the tropics but usually requires repeated shots. For practical reasons a live vaccine format should probably be pursued, which could then be combined with a yellow fever vaccine, using the same cold chains, since this disease occupies the same endemic areas in West Africa. Lassa vaccine initiatives have suffered from a lack of funding in the past but bioterrorism has brought new resources to Lassa virus science. Adequate funding and applications of new vaccine technologies give hope that we may soon see a vaccine in clinical trials. However, the difficulty of conducting trials in endemic areas and lack of political stability remain serious problems.
Fisher-Hoch
Susan P
SP
University of Texas Houston Health Science Center, School of Public Health, Brownsville Regional Campus, 80 Fort Brown, Brownsville, Texas 78520, USA. sfisherhoch@utb.edu
McCormick
Joseph B
JB
D000354:Africa, Western / Q000453:epidemiology; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D007835:Lassa Fever / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D007836:Lassa virus / Q000276:immunology; D012254:Ribavirin / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology*
D000998:Antiviral Agents; D014765:Viral Vaccines; D012254:Ribavirin